The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 15, 2022

Filed:

Aug. 22, 2017
Applicants:

Variation Biotechnologies Inc., Ottawa, CA;

Sorbonne Université, Paris, FR;

Inventors:

David E. Anderson, Newton, MA (US);

Anne-Catherine Fluckiger, Saint Genis les Ollières, FR;

David Klatzmann, Paris, FR;

Charlotte Dalba-Fribert, Gothenburg, SE;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61P 31/22 (2006.01); C07K 14/005 (2006.01); A61K 39/245 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/245 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C12N 2710/16134 (2013.01); C12N 2740/13023 (2013.01); C12N 2760/20234 (2013.01);
Abstract

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).


Find Patent Forward Citations

Loading…